Professor Richard Haynes
Professor of Renal Medicine and Clinical Trials
- MRC Population Health Research Unit Programme Leader: Randomised Trials in Cardiovascular and Metabolic Disease
- MSc in Global Health Science module 8 lead: Clinical Trials and Meta-Analysis
Richard Haynes did his pre-clinical medical studies in Cambridge before moving to Oxford for his clinical studies and qualified in 2000. He came to CTSU for a period of “out of programme” research in 2006 to work on the HPS2-THRIVE trial with Prof Jane Armitage. He completed his training in renal medicine in 2011 and was appointed as an honorary consultant at the Oxford Kidney Unit. Shortly after that he was appointed to the MRC Programme Leader track and he is now Programme Leader in the MRC Population Health Research Unit for the programme in Randomised Trials in Cardiovascular and Metabolic Disease.
Effect of hydroxychloroquine in hospitalized patients with COVID-19
LANDRAY M. and HORBY P., (2020), New England Journal of Medicine
International consensus definitions of clinical trial outcomes for kidney failure: 2020
Levin A. et al, (2020), Kidney International, 98, 849 - 859
Lopinavir-ritonavir in Hospitalised Patients with COVID-19 – a randomised, controlled, open-label, platform trial
LINSELL L. et al, (2020), The Lancet
CONVENTIONAL AND GENETIC EVIDENCE ON THE ASSOCIATION BETWEEN ADIPOSITY AND CHRONIC KIDNEY DISEASE
HERRINGTON W. et al, (2020), Journal of the American Society of Nephrology
Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis.
WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group None. et al, (2020), JAMA